RS58351B1 - C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze - Google Patents

C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze

Info

Publication number: RS58351B1
Authority: RS; Serbia
Prior art keywords: deficency; prevention; treatment; methods; disorders associated
Prior art date: 2013-03-15

Application number

RS20190198A

Other languages

English (en)

Inventor

Cynthia Gallagher

Stephen Ruddy

Mark Cornell Manning

Original Assignee

Shire Viropharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-17

Publication date

2019-03-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS58351(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-17 Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc

2019-03-29 Publication of RS58351B1 publication Critical patent/RS58351B1/sr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Marine Sciences & Fisheries (AREA)
Cell Biology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

RS20190198A 2013-03-15 2014-03-17 C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze RS58351B1 (sr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361791399P	2013-03-15	2013-03-15
EP17177676.8A EP3290046B1 (en)	2013-03-15	2014-03-17	C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency

Publications (1)

Publication Number	Publication Date
RS58351B1 true RS58351B1 (sr)	2019-03-29

Family

ID=51538486

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RS20190198A RS58351B1 (sr)	2013-03-15	2014-03-17	C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
RS20170802A RS56285B1 (sr)	2013-03-15	2014-03-17	C1-inh kompozicije za upotrebu u prevenciji i lečenju naslednog angioedema (hae)

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
RS20170802A RS56285B1 (sr)	2013-03-15	2014-03-17	C1-inh kompozicije za upotrebu u prevenciji i lečenju naslednog angioedema (hae)

Country Status (31)

Country	Link
US (9)	US9616111B2 (sr)
EP (3)	EP3290046B1 (sr)
JP (9)	JP6184581B2 (sr)
KR (4)	KR102430453B1 (sr)
CN (2)	CN111529708A (sr)
AU (3)	AU2014232912A1 (sr)
BR (1)	BR112015023207A8 (sr)
CA (2)	CA2904543C (sr)
CY (2)	CY1119419T1 (sr)
DE (1)	DE202014011208U1 (sr)
DK (2)	DK3290046T3 (sr)
EA (1)	EA201591278A1 (sr)
ES (2)	ES2713004T3 (sr)
GB (1)	GB2530921B (sr)
HK (1)	HK1250912B (sr)
HR (2)	HRP20171269T1 (sr)
HU (2)	HUE041837T2 (sr)
IL (2)	IL241549B (sr)
LT (2)	LT2968434T (sr)
ME (2)	ME02865B (sr)
MX (3)	MX373965B (sr)
NZ (2)	NZ710730A (sr)
PL (2)	PL3290046T3 (sr)
PT (2)	PT2968434T (sr)
RS (2)	RS58351B1 (sr)
SG (2)	SG10201707598QA (sr)
SI (2)	SI3290046T1 (sr)
SM (2)	SMT201700415T1 (sr)
TR (1)	TR201900319T4 (sr)
WO (1)	WO2014145519A2 (sr)
ZA (3)	ZA201507604B (sr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10201707598QA (en)	2013-03-15	2017-10-30	Shire Viropharma Inc	C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
RS58343B1 (sr) *	2013-11-22	2019-03-29	Shire Viropharma Inc	Postupci lečenja odbacivanja posredovanog antitelima pacijenata sa transplatiranim organom sa inhibitorom c1-esteraze
EP3258911A1 (en) *	2015-02-20	2017-12-27	CSL Behring GmbH	Pharmaceutical formulations of c1 esterase inhibitor
HK1250623A1 (zh) *	2015-05-28	2019-01-11	Cornell University	腺相關病毒介導的c1ei遞送作為用於血管性水腫的療法
BR112018010160A8 (pt) *	2015-11-19	2019-02-26	Shire Human Genetic Therapies	inibidor da c1 esterase humana recombinante e usos do mesmo
WO2018024873A1 (en)	2016-08-05	2018-02-08	Csl Behring Gmbh	Pharmaceutical formulations of c1 esterase inhibitor
WO2018037046A1 (en) *	2016-08-23	2018-03-01	Csl Behring Gmbh	Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
EP3624833A1 (en)	2017-05-16	2020-03-25	Octapharma AG	C1-esterase inhibitor preparation
AU2019226355A1 (en)	2018-02-28	2020-09-17	Pharming Intellectual Property B.V.	Treatment and prevention of pre-eclampsia
WO2019166572A1 (en)	2018-02-28	2019-09-06	Pharming Intellectual Property B.V.	Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
AU2019288683A1 (en)	2018-06-22	2021-01-21	Junten Bio Co., Ltd.	Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
AU2019288684A1 (en)	2018-06-22	2021-01-21	Junten Bio Co., Ltd.	Composition for eliciting infectious immunological tolerance
KR20210025062A (ko)	2018-06-22	2021-03-08	가부시키가이샤 준텐 바이오	면역 관용을 유도하는 항체, 유도된 림프구, 또한 유도된 림프구를 이용하는 세포 치료제 치료법
US20230041642A1 (en) *	2019-12-16	2023-02-09	Nipro Corporation	Aggregation Inhibitory Agent and Medical Composition and Medical Device Including Same
EP3895726A1 (en)	2020-04-17	2021-10-20	Pharming Intellectual Property BV	Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
WO2023280981A1 (en)	2021-07-09	2023-01-12	Pharming Intellectual Property B.V.	Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko)	2021-09-29	2023-04-05	주식회사 엘지에너지솔루션	배터리 제어 시스템 및 방법
WO2025090843A1 (en) *	2023-10-27	2025-05-01	Kansas State University Research Foundation	Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) *	2025-03-14	2025-06-03	深圳市卫光生物制品股份有限公司	一种c1酯酶抑制剂重组变体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304482A (en)	1989-03-06	1994-04-19	The Board Of Regents Of The University Of Texas System	Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE69429816T2 (de)	1993-09-01	2002-09-19	Stichting Sanquin Bloedvoorziening, Amsterdam	C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
JP2000507204A (ja)	1995-12-18	2000-06-13	ステイヒテイング・サンキン・ブロードボールジーニング	Ｃ１―インヒビターの補体及び血液凝固阻害特性の強化
AT409336B (de)	1999-12-22	2002-07-25	Baxter Ag	Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
US7067713B2 (en)	2000-01-31	2006-06-27	Pharming Intellectual Property B.V.	C1 Inhibitor produced in the milk of transgenic non-human mammals
DE60132169T2 (de)	2000-01-31	2008-12-11	Pharming Intellectual Property Bv	Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
CA2423227C (en)	2000-10-12	2011-11-29	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
DE10112617A1 (de)	2001-03-14	2002-10-02	Aventis Behring Gmbh	Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
WO2004034971A2 (en)	2002-09-25	2004-04-29	The Center For Blood Research, Inc.	Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en)	2003-05-15	2004-12-23	Cbr Institute For Biomedical Research, Inc.	Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
ES2830499T3 (es)	2003-05-16	2021-06-03	Pharming Intellectual Property B V	Inhibidor de C1 con una semivida corta para un tratamiento transitorio
US20060233776A1 (en)	2003-08-19	2006-10-19	Norbert Heimburger	C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en)	2003-09-11	2013-08-06	The Board Of Regents Of The University Of Texas System	Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en)	2004-05-18	2005-11-23	Georg Dewald	Methods and kits to detect Hereditary angioedema type III
CA2654440C (en)	2005-06-06	2013-09-03	Girish J. Kotwal	Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
ES2400306T3 (es)	2005-10-21	2013-04-09	Catalyst Biosciences, Inc.	Proteasas modificadas que inhiben la activación del complemento
AU2006327989B2 (en)	2005-12-21	2012-06-07	Pharming Intellectual Property Bv	Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
DK1965831T3 (da) *	2005-12-21	2011-10-24	Pharming Intellectual Pty Bv	Anvendelse af C1-inhibitor til forebyggelse af iskæmi-reperfusionsskade
US7837992B2 (en)	2006-06-22	2010-11-23	Beth Israel Deaconess Medical Center	C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
EP2109457B1 (en)	2007-02-12	2016-01-06	CSL Behring GmbH	Therapeutic application of kazal-type serine protease inhibitors
NZ709704A (en)	2007-11-30	2017-03-31	Abbvie Biotechnology Ltd	Protein formulations and methods of making same
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
US20100143325A1 (en)	2008-12-09	2010-06-10	Vascular Laboratory, Inc.	Composition And Methods Involving Thrombolytic Agents
CA2767105A1 (en)	2009-07-02	2011-01-06	Musc Foundation For Research Development	Methods of stimulating liver regeneration
CA2777845C (en)	2009-10-16	2017-08-01	Omeros Corporation	Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
JP6148013B2 (ja)	2010-03-05	2017-06-14	リグショスピタレト	補体活性化のキメラ抑制分子
WO2011116291A1 (en) *	2010-03-18	2011-09-22	Thrombolytic Science International	Production of human c1 inhibitor in human cells
WO2013013017A2 (en) *	2011-07-21	2013-01-24	Alnylam Pharmaceuticals, Inc.	Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
US10471142B2 (en)	2011-09-24	2019-11-12	Csl Behring Gmbh	Combination therapy using immunoglobulin and C1-Inhibitor
EP2793935B1 (en) *	2011-12-22	2016-05-25	CSL Behring GmbH	Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
EP2838550A1 (en)	2012-03-16	2015-02-25	Belrose Pharma Inc.	Polymeric conjugates of c1-inhibitors
US20160033511A1 (en)	2013-03-13	2016-02-04	Creatics Llc	Methods and compositions for detecting pancreatic cancer
SG10201707598QA (en) *	2013-03-15	2017-10-30	Shire Viropharma Inc	C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
JP6935245B2 (ja) *	2017-06-29	2021-09-15	大和ハウス工業株式会社	収容ラック
JP6889626B2 (ja) *	2017-06-29	2021-06-18	トキコシステムソリューションズ株式会社	燃料供給システム

2014
- 2014-03-17 SG SG10201707598QA patent/SG10201707598QA/en unknown
- 2014-03-17 HU HUE17177676A patent/HUE041837T2/hu unknown
- 2014-03-17 SI SI201431032T patent/SI3290046T1/sl unknown
- 2014-03-17 ES ES17177676T patent/ES2713004T3/es active Active
- 2014-03-17 RS RS20190198A patent/RS58351B1/sr unknown
- 2014-03-17 SM SM20170415T patent/SMT201700415T1/it unknown
- 2014-03-17 PT PT147623433T patent/PT2968434T/pt unknown
- 2014-03-17 EA EA201591278A patent/EA201591278A1/ru unknown
- 2014-03-17 ME MEP-2017-182A patent/ME02865B/me unknown
- 2014-03-17 PL PL17177676T patent/PL3290046T3/pl unknown
- 2014-03-17 SG SG11201507616VA patent/SG11201507616VA/en unknown
- 2014-03-17 KR KR1020217033628A patent/KR102430453B1/ko active Active
- 2014-03-17 PT PT17177676T patent/PT3290046T/pt unknown
- 2014-03-17 TR TR2019/00319T patent/TR201900319T4/tr unknown
- 2014-03-17 WO PCT/US2014/030309 patent/WO2014145519A2/en active Application Filing
- 2014-03-17 KR KR1020217004777A patent/KR20210021146A/ko not_active Ceased
- 2014-03-17 ME MEP-2019-45A patent/ME03326B/me unknown
- 2014-03-17 EP EP17177676.8A patent/EP3290046B1/en active Active
- 2014-03-17 BR BR112015023207A patent/BR112015023207A8/pt not_active Application Discontinuation
- 2014-03-17 DK DK17177676.8T patent/DK3290046T3/en active
- 2014-03-17 CA CA2904543A patent/CA2904543C/en active Active
- 2014-03-17 DE DE202014011208.8U patent/DE202014011208U1/de not_active Expired - Lifetime
- 2014-03-17 NZ NZ710730A patent/NZ710730A/en unknown
- 2014-03-17 MX MX2015011281A patent/MX373965B/es active IP Right Grant
- 2014-03-17 CN CN202010362851.6A patent/CN111529708A/zh active Pending
- 2014-03-17 AU AU2014232912A patent/AU2014232912A1/en not_active Abandoned
- 2014-03-17 JP JP2016503371A patent/JP6184581B2/ja active Active
- 2014-03-17 NZ NZ751555A patent/NZ751555A/en unknown
- 2014-03-17 RS RS20170802A patent/RS56285B1/sr unknown
- 2014-03-17 KR KR1020157022897A patent/KR20150135242A/ko not_active Ceased
- 2014-03-17 GB GB1519921.9A patent/GB2530921B/en active Active
- 2014-03-17 SI SI201430368T patent/SI2968434T1/sl unknown
- 2014-03-17 DK DK14762343.3T patent/DK2968434T3/en active
- 2014-03-17 PL PL14762343T patent/PL2968434T3/pl unknown
- 2014-03-17 LT LTEP14762343.3T patent/LT2968434T/lt unknown
- 2014-03-17 HR HRP20171269TT patent/HRP20171269T1/hr unknown
- 2014-03-17 ES ES14762343.3T patent/ES2639833T3/es active Active
- 2014-03-17 CN CN201480014712.7A patent/CN105517559A/zh active Pending
- 2014-03-17 EP EP14762343.3A patent/EP2968434B1/en not_active Revoked
- 2014-03-17 LT LTEP17177676.8T patent/LT3290046T/lt unknown
- 2014-03-17 EP EP18206413.9A patent/EP3508213A1/en not_active Withdrawn
- 2014-03-17 KR KR1020227016244A patent/KR102579789B1/ko active Active
- 2014-03-17 HU HUE14762343A patent/HUE036224T2/hu unknown
- 2014-03-17 SM SM20190141T patent/SMT201900141T1/it unknown
- 2014-03-17 CA CA3054718A patent/CA3054718A1/en not_active Abandoned
- 2014-03-17 MX MX2020004724A patent/MX389449B/es unknown
2015
- 2015-08-28 MX MX2021011946A patent/MX2021011946A/es unknown
- 2015-09-10 IL IL241549A patent/IL241549B/en active IP Right Grant
- 2015-09-15 US US14/855,168 patent/US9616111B2/en active Active
- 2015-10-13 ZA ZA2015/07604A patent/ZA201507604B/en unknown
2017
- 2017-01-20 US US15/411,744 patent/US20170224788A1/en not_active Abandoned
- 2017-03-16 JP JP2017051361A patent/JP6422520B2/ja active Active
- 2017-09-12 CY CY20171100961T patent/CY1119419T1/el unknown
- 2017-10-12 ZA ZA2017/06929A patent/ZA201706929B/en unknown
- 2017-12-11 US US15/837,969 patent/US10201595B2/en active Active
- 2017-12-11 US US15/837,693 patent/US10105423B2/en active Active
- 2017-12-11 US US15/837,938 patent/US10130690B2/en active Active
- 2017-12-11 US US15/837,677 patent/US10080788B2/en active Active
2018
- 2018-04-06 JP JP2018073689A patent/JP6473534B2/ja active Active
- 2018-04-06 JP JP2018073691A patent/JP6473536B2/ja active Active
- 2018-04-06 JP JP2018073690A patent/JP6473535B2/ja active Active
- 2018-08-02 US US16/053,457 patent/US11534482B2/en active Active
- 2018-08-10 HK HK18110262.0A patent/HK1250912B/en unknown
- 2018-09-05 US US16/122,015 patent/US20190160158A1/en not_active Abandoned
- 2018-09-17 AU AU2018229558A patent/AU2018229558B2/en active Active
- 2018-10-12 ZA ZA2018/06793A patent/ZA201806793B/en unknown
2019
- 2019-01-25 JP JP2019011079A patent/JP6877470B2/ja active Active
- 2019-01-25 JP JP2019011084A patent/JP6877472B2/ja active Active
- 2019-01-25 JP JP2019011082A patent/JP6877471B2/ja active Active
- 2019-02-11 HR HRP20190270TT patent/HRP20190270T1/hr unknown
- 2019-03-15 CY CY20191100308T patent/CY1121653T1/el unknown
- 2019-10-02 US US16/591,184 patent/US11364288B2/en active Active
2020
- 2020-05-15 AU AU2020203183A patent/AU2020203183B2/en active Active
- 2020-07-19 IL IL276153A patent/IL276153B/en unknown
2021
- 2021-03-02 JP JP2021032716A patent/JP2021088599A/ja active Pending

Also Published As

Publication number	Publication date
JP2019073546A (ja)	2019-05-16
NZ751555A (en)	2021-07-30
GB2530921B (en)	2017-09-20
AU2020203183B2 (en)	2022-06-02
US20180153972A1 (en)	2018-06-07
JP2018119000A (ja)	2018-08-02
MX373965B (es)	2020-07-13
EP2968434B1 (en)	2017-06-28
ZA201806793B (en)	2020-01-29
JP2019073545A (ja)	2019-05-16
JP6184581B2 (ja)	2017-08-23
PL2968434T3 (pl)	2018-01-31
ZA201507604B (en)	2018-05-30
KR20210129267A (ko)	2021-10-27
EP3290046A1 (en)	2018-03-07
US10080788B2 (en)	2018-09-25
US20180085441A1 (en)	2018-03-29
US11534482B2 (en)	2022-12-27
EA201591278A1 (ru)	2016-03-31
EP2968434A2 (en)	2016-01-20
SMT201700415T1 (it)	2017-11-15
US20170224788A1 (en)	2017-08-10
CA3054718A1 (en)	2014-09-18
US20190160158A1 (en)	2019-05-30
EP3290046B1 (en)	2019-01-02
WO2014145519A3 (en)	2014-12-31
AU2018229558B2 (en)	2020-03-05
JP2021088599A (ja)	2021-06-10
HK1250912B (en)	2020-01-10
JP2019073544A (ja)	2019-05-16
EP2968434A4 (en)	2016-03-02
SG11201507616VA (en)	2015-10-29
MX2015011281A (es)	2016-03-03
KR102430453B1 (ko)	2022-08-05
LT2968434T (lt)	2017-09-25
BR112015023207A2 (pt)	2017-11-21
LT3290046T (lt)	2019-03-12
CN111529708A (zh)	2020-08-14
WO2014145519A2 (en)	2014-09-18
IL241549B (en)	2020-08-31
AU2014232912A1 (en)	2015-09-03
RS56285B1 (sr)	2017-12-29
US10201595B2 (en)	2019-02-12
US20180110843A1 (en)	2018-04-26
HRP20190270T1 (hr)	2019-04-05
CY1119419T1 (el)	2018-03-07
CN105517559A (zh)	2016-04-20
DK3290046T3 (en)	2019-03-18
KR102579789B1 (ko)	2023-09-15
ME03326B (me)	2019-10-20
TR201900319T4 (tr)	2019-02-21
US20180110844A1 (en)	2018-04-26
AU2018229558A1 (en)	2018-10-04
DE202014011208U1 (de)	2018-08-23
US11364288B2 (en)	2022-06-21
US20200261556A1 (en)	2020-08-20
DK2968434T3 (en)	2017-09-11
CA2904543C (en)	2019-10-08
PL3290046T3 (pl)	2019-05-31
GB2530921A (en)	2016-04-06
SG10201707598QA (en)	2017-10-30
US20160015795A1 (en)	2016-01-21
IL276153B (en)	2022-06-01
GB201519921D0 (en)	2015-12-23
KR20220070049A (ko)	2022-05-27
US10105423B2 (en)	2018-10-23
SI3290046T1 (sl)	2019-04-30
IL276153A (en)	2020-09-30
MX2021011946A (es)	2021-11-17
ZA201706929B (en)	2019-05-29
JP6877472B2 (ja)	2021-05-26
JP2018119001A (ja)	2018-08-02
JP6422520B2 (ja)	2018-11-14
KR20150135242A (ko)	2015-12-02
JP6877470B2 (ja)	2021-05-26
CY1121653T1 (el)	2020-07-31
EP3508213A1 (en)	2019-07-10
JP2016516073A (ja)	2016-06-02
AU2020203183A1 (en)	2020-06-04
ES2713004T3 (es)	2019-05-17
PT3290046T (pt)	2019-02-18
HK1220403A1 (en)	2017-05-05
HRP20171269T1 (hr)	2017-11-03
KR20210021146A (ko)	2021-02-24
SI2968434T1 (sl)	2017-11-30
CA2904543A1 (en)	2014-09-18
MX2020004724A (es)	2022-01-18
HUE041837T2 (hu)	2019-05-28
JP6473536B2 (ja)	2019-02-20
ES2639833T3 (es)	2017-10-30
PT2968434T (pt)	2017-09-18
JP6877471B2 (ja)	2021-05-26
JP6473534B2 (ja)	2019-02-20
HUE036224T2 (hu)	2018-06-28
BR112015023207A8 (pt)	2018-01-23
MX389449B (es)	2025-03-20
ME02865B (me)	2018-04-20
JP6473535B2 (ja)	2019-02-20
NZ710730A (en)	2021-07-30
US10130690B2 (en)	2018-11-20
JP2018119002A (ja)	2018-08-02
US20190160157A1 (en)	2019-05-30
SMT201900141T1 (it)	2019-05-10
US9616111B2 (en)	2017-04-11
JP2017105847A (ja)	2017-06-15

Publication	Publication Date	Title
HRP20190270T1 (hr)	2019-04-05	C1-inh pripravci i postupci za prevenciju i liječenje poremećaja povezanih s nedostatkom inhibitora c1 esteraze
EP2968318A4 (en)	2016-12-14	ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES
EP3182989A4 (en)	2018-04-11	Methods and compositions for the prevention and treatment of disease
SG11201702554QA (en)	2017-04-27	Compositions and methods for the treatment of multiple sclerosis
IL244621A (en)	2017-04-30	Preparations for the treatment of hypertension and / or fibrosis
IL244622A0 (en)	2016-04-21	Preparations for the treatment of hypertension and/or fibrosis
PL2968478T3 (pl)	2019-01-31	Kompozycje i sposoby do leczenia karboksyhemoglobinemii
ZA201408062B (en)	2016-04-28	Compositions and methods for the treatment of multiple sclerosis
ZA201900984B (en)	2019-12-18	Methods and compositions for the treatment of warts
EP2994147A4 (en)	2017-03-08	Compositions and methods for the treatment of tinnitus
EP2934501A4 (en)	2016-06-01	USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES
IL245549A0 (en)	2016-06-30	Compositions and methods for preventing and/or treating disorders associated with dennd1a variant 2
EP3068431A4 (en)	2017-08-23	Methods and compositions for the treatment of hcmv
EP3225237A4 (en)	2018-12-05	Fatty acid amides for the prevention and/or treatment of steatohepatitis
EP3104940A4 (en)	2017-07-26	Compositions and methods for the prevention and/or treatment of schistosomiasis
AU2013904048A0 (en)	2013-11-07	Compositions and methods for the prevention and/or treatment of neurogenic inflammation and/or infla
PL3273997T3 (pl)	2019-12-31	Kompozycja do leczenia nieżytu nosa
SG11201704282UA (en)	2017-06-29	Compositions and methods for the treatment of multiple sclerosis
HK1231001A1 (en)	2017-12-15	Compositions and methods for the prevention and/or treatment of schistosomiasis
AU2013901658A0 (en)	2013-05-30	Compositions and methods for the treatment of tinnitus
AU2013903571A0 (en)	2013-09-26	Compositions for the treatment of hypertension and/or fibrosis